drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous chimeric antigen receptor T-cell therapy targeting CD19-expressing large B-cell lymphomas; administered prior to golcadomide.
nci_thesaurus_concept_id
C176018
nci_thesaurus_preferred_term
Anti-CD19 CAR T Cells Preparation
nci_thesaurus_definition
Any preparation of CAR-T cells that targets CD19.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor that recognizes CD19 on B cells. CAR engagement of CD19 triggers CD3ζ and costimulatory signaling (e.g., CD28 or 4-1BB), leading to T‑cell activation, proliferation, cytokine release, and cytotoxic killing of CD19‑positive malignant B cells via perforin/granzyme and apoptosis pathways, resulting in depletion of CD19+ tumor cells (and on-target B‑cell aplasia).
drug_name
Anti-CD19 CAR T cells
nct_id_drug_ref
NCT06271057